Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SANUWAVE Health (SNWV) Current Deferred Revenue (2016 - 2026)

SANUWAVE Health has reported Current Deferred Revenue over the past 11 years, most recently at $487000.0 for Q1 2026.

  • Quarterly Current Deferred Revenue rose 151.03% to $487000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $487000.0 through Mar 2026, up 151.03% year-over-year, with the annual reading at $388000.0 for FY2025, 21.3% down from the prior year.
  • Current Deferred Revenue was $487000.0 for Q1 2026 at SANUWAVE Health, up from $388000.0 in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $493000.0 in Q4 2024 and troughed at $58000.0 in Q1 2022.
  • The 5-year median for Current Deferred Revenue is $194000.0 (2025), against an average of $221352.9.
  • Year-over-year, Current Deferred Revenue skyrocketed 522.5% in 2022 and then plummeted 72.69% in 2023.
  • A 5-year view of Current Deferred Revenue shows it stood at $290000.0 in 2022, then soared by 51.38% to $439000.0 in 2023, then rose by 12.3% to $493000.0 in 2024, then dropped by 21.3% to $388000.0 in 2025, then grew by 25.52% to $487000.0 in 2026.
  • Per Business Quant, the three most recent readings for SNWV's Current Deferred Revenue are $487000.0 (Q1 2026), $388000.0 (Q4 2025), and $299000.0 (Q3 2025).